Tag - HIND

Developments

Vyome to present compelling data on treatment for MFW at AACR

Vyome Holdings (NASDAQ: HIND) has announced it will present its full Phase 2 investigator-initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor...

April 6, 2026

Developments

Vyome announces positive interim data on VT-1953 in MFW

Vyome Holdings (NASDAQ: HIND) has announced the interim results from its investigator –initiated Phase 2 Proof of Concept study of VT-1953 topical gel in patients with malignant fungating wounds (MFW). According to...

September 4, 2025

Tag - HIND

Vyome to present compelling data on treatment for MFW at AACR

Vyome announces positive interim data on VT-1953 in MFW

Subscribe